Omni Bio Pharmaceutical (OMBP) Stock Price, News & Analysis

Company Overview

Omni Bio Pharmaceutical, Inc. (OTCMKTS: OMBP) is a development‐stage specialty biopharmaceutical company focused on in‐licensing, developing and commercializing novel drug delivery systems and therapeutic formulations. The company’s platform technologies are designed to enhance the localized delivery of active pharmaceutical ingredients, with a primary emphasis on topical and transdermal products targeting dermatological conditions and central nervous system disorders. Through proprietary formulations, Omni Bio aims to improve patient compliance and therapeutic outcomes while minimizing systemic side effects.

To support its pipeline, Omni Bio Pharmaceutical has established strategic partnerships and licensing agreements with contract manufacturers and research institutions. These collaborations enable the company to advance its product candidates through preclinical testing and early‐phase clinical studies. In parallel, Omni Bio seeks out‐licensing opportunities that allow larger pharmaceutical companies to commercialize its delivery technologies on a global scale, thereby leveraging existing sales and distribution networks.

Headquartered in Silver Spring, Maryland, Omni Bio Pharmaceutical currently operates primarily within North America, with a strategic intent to expand internationally via licensing and distribution alliances. The company’s leadership team brings together expertise in drug development, regulatory strategy and business development, positioning Omni Bio to progress its pipeline toward milestone‐driven value creation and potential commercialization partnerships.

Key Stats

• Today's Range: $0.0010 to $0.0010
• 50-Day Range: N/A
• 52-Week Range: $0.00 to $0.04
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 5/08/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:OMBP
• CIK: 1389870
• Web: www.omnibiopharma.com
• Phone: 970-237-5178
• Fax: N/A
• Employees: 1
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A